Retail prices for 260 widely used brand-name prescription drugs last year increased by an average 2.9%, more than twice the general rate of inflation, according to a report released yesterday by AARP’s Public Policy Institute.
 
“Increases in the retail price of brand name prescription drugs have a corresponding impact on the cost of therapy for the individual and for all other payers,” the authors note. “In 2020, the average cost of therapy for a brand name prescription drug, based on the market basket in this study, was $6,600 per year.”
 
A second AARP PPI analysis found that Medicare Part D spent nearly $40 billion more on 50 top brand-name drugs between 2015 and 2019 because drug price increases exceeded inflation.

 

Related News Articles

Headline
The Centers for Medicare & Medicaid Services Dec. 19 issued two proposed rules for implementing alternative drug pricing models. The first proposed…
Headline
The White House announced Dec. 19 that it reached most-favored-nation deals with nine pharmaceutical companies, aligning their drug prices with the lowest paid…
Headline
An AHA blog examines new data released by the Health Resources and Services Administration on the growth of the 340B Drug Pricing Program.  “When…
Headline
The Trump administration announced a trade agreement with the U.K. Dec. 1 on pharmaceuticals that exempts U.K. drug products from Section 232 tariffs. In…
Headline
The Centers for Medicare & Medicaid Services Nov. 25 announced lower prices for 15 Medicare Part D drugs selected for the second cycle of negotiations…
Headline
The White House announced today that it reached agreements with Eli Lilly and Novo Nordisk to align their drug prices with the lowest paid by other developed…